Amylin agonist for treating depression, anxiety disorder and schizophrenia
View Patent ↗Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
1. A method for treating depression in a human in need thereof comprising administering to the human a therapeutically effective amount of an amylin agonist analog comprising the amino acid sequence of SEQ ID NO:159 to treat depression.
2. A method for treating depression, an anxiety disorder, or schizophrenia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an amylin agonist analog having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:159 to treat depression, the anxiety disorder, or schizophrenia.
3. A method for treating depression in a human in need thereof comprising administering to the human a therapeutically effective amount of an amylin agonist analog having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:159 to treat depression.